Literature DB >> 17939148

Insight into the kinetic of amyloid beta (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action.

Manuela Bartolini1, Carlo Bertucci, Maria Laura Bolognesi, Andrea Cavalli, Carlo Melchiorre, Vincenza Andrisano.   

Abstract

The initial transition of amyloid beta (1-42) (Abeta42) soluble monomers/small oligomers from unordered/alpha-helix to a beta-sheet-rich conformation represents a suitable target to design new potent inhibitors and to obtain effective therapeutics for Alzheimer's disease. Under optimized conditions, this reliable and reproducible CD kinetic study showed a three-step sigmoid profile that was characterized by a lag phase (prevailing unordered/alpha-helix conformation), an exponential growth phase (increasing beta-sheet secondary structure) and a plateau phase (prevailing beta-sheet secondary structure). This kinetic analysis brought insight into the inhibitors' mechanism of action. In fact, an increase in the duration of the lag phase can be related to the formation of an inhibitor-Abeta complex, in which the non-amyloidogenic conformation is stabilized. When the exponential rate is affected exclusively, such as in the case of Congo red and tetracycline, then the inhibitor affinity might be higher for the pleated beta-sheet structure. Finally, by adding the inhibitor at the end of the exponential phase, the soluble protofibrils can be disrupted and the Abeta amyloidogenic structure can revert into monomers/small oligomers. Congo red and tetracycline preferentially bind to amyloid in the beta-sheet conformation because both decreased the slope of the exponential growth, even if to a different extent, whereas no effect was observed for tacrine and galantamine. Some very preliminary indications can be derived about the structural requirements for binding to nonamyloidogenic or beta-sheet amyloid secondary structure for the development of potent antiaggregating agents. On these premises, memoquin, a multifunctional molecule that was designed to become a drug candidate for the treatment of Alzheimer's disease, was investigated under the reported circular dichroism assay and its anti-amyloidogenic mechanism of action was elucidated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17939148     DOI: 10.1002/cbic.200700427

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  55 in total

1.  Effects of Congo red on aβ(1-40) fibril formation process and morphology.

Authors:  Partha Pratim Bose; Urmimala Chatterjee; Ling Xie; Jan Johansson; Emmanuelle Göthelid; Per I Arvidsson
Journal:  ACS Chem Neurosci       Date:  2010-02-03       Impact factor: 4.418

2.  Protective spin-labeled fluorenes maintain amyloid beta peptide in small oligomers and limit transitions in secondary structure.

Authors:  Robin Altman; Sonny Ly; Silvia Hilt; Jitka Petrlova; Izumi Maezawa; Tamás Kálai; Kálmán Hideg; Lee-Way Jin; Ted A Laurence; John C Voss
Journal:  Biochim Biophys Acta       Date:  2015-09-14

Review 3.  Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease.

Authors:  Qin Nie; Xiao-guang Du; Mei-yu Geng
Journal:  Acta Pharmacol Sin       Date:  2011-04-18       Impact factor: 6.150

4.  Oligomerization Alters Binding Affinity Between Amyloid Beta and a Modulator of Peptide Aggregation.

Authors:  Silvia Hilt; Tatu Rojalin; Tapani Viitala; Artturi Koivuniemi; Alex Bunker; Sebastian Wachsmann Hogiu; Tamás Kálai; Kálmán Hideg; Marjo Yliperttula; John C Voss
Journal:  J Phys Chem C Nanomater Interfaces       Date:  2017-10-10       Impact factor: 4.126

5.  Computational and experimental studies on β-sheet breakers targeting Aβ1-40 fibrils.

Authors:  Velia Minicozzi; Roberta Chiaraluce; Valerio Consalvi; Cesare Giordano; Claudia Narcisi; Pasqualina Punzi; Giancarlo C Rossi; Silvia Morante
Journal:  J Biol Chem       Date:  2014-02-28       Impact factor: 5.157

6.  Ceftriaxone blocks the polymerization of α-synuclein and exerts neuroprotective effects in vitro.

Authors:  Paolo Ruzza; Giuliano Siligardi; Rohanah Hussain; Anna Marchiani; Mehmet Islami; Luigi Bubacco; Giovanna Delogu; Davide Fabbri; Maria A Dettori; Mario Sechi; Nicolino Pala; Ylenia Spissu; Rossana Migheli; Pier A Serra; GianPietro Sechi
Journal:  ACS Chem Neurosci       Date:  2013-10-24       Impact factor: 4.418

7.  Inhibition of Alzheimer's amyloid toxicity with a tricyclic pyrone molecule in vitro and in vivo.

Authors:  Hyun-Seok Hong; Sandeep Rana; Lydia Barrigan; Aibin Shi; Yi Zhang; Feimeng Zhou; Lee-Way Jin; Duy H Hua
Journal:  J Neurochem       Date:  2009-02       Impact factor: 5.372

8.  Influence of methionine-ruthenium complex on the fibril formation of human islet amyloid polypeptide.

Authors:  Gehui Gong; Jufei Xu; Xiangyi Huang; Weihong Du
Journal:  J Biol Inorg Chem       Date:  2019-01-30       Impact factor: 3.358

9.  Reversal of temperature-induced conformational changes in the amyloid-beta peptide, Abeta40, by the beta-sheet breaker peptides 16-23 and 17-24.

Authors:  Funda F Bölükbaşi Hatip; Midori Suenaga; Tatsuo Yamada; Yoichi Matsunaga
Journal:  Br J Pharmacol       Date:  2009-09-25       Impact factor: 8.739

10.  The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?

Authors:  Kerensa Broersen; Frederic Rousseau; Joost Schymkowitz
Journal:  Alzheimers Res Ther       Date:  2010-07-14       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.